S&P Futures
4,033.75 +32.25 (+0.81%) Dow Futures
32,791.00 +203.00 (+0.62%) Nasdaq Futures
12,835.25 +102.75 (+0.81%) Russell 2000 Futures
1,783.60 +18.80 (+1.07%) Crude Oil
73.75 +0.55 (+0.75%) Gold
1,964.00 -9.50 (-0.48%)
Abeona Therapeutics Inc. (ABEO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.7200 |
| Open | 2.7300 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1100 |
| Day's Range | 2.7300 - 3.0900 |
| 52 Week Range | 2.1900 - 9.2500 |
| Volume | |
| Avg. Volume | 199,098 |
| Market Cap | 47.749M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9090 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.00 |
- GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to accept employment, which equity awards relate to, in the aggregate, up to 131,750 restricted shares of Abeona common stock. One-quarter (1/4) of the shares subject to such restricted stock awards vesting on th
- GlobeNewswire
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the inaugural International Societies for Investigative Dermatology (ISID) Meeting, being held May 10-13, 2023 in Tokyo, Japan. Abeona previously reported positive top-line efficacy and safety data from the VIITAL s
- GlobeNewswire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (ADOA) To submit first pre-Investigational New Drug (IND) application meeting request this month NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from
